Testing the right target and right drug at the right stage

Reisa A. Sperling, Clifford R. Jack, Paul S. Aisen

Research output: Contribution to journalComment/debate

303 Scopus citations

Abstract

Alzheimer's disease (AD) is the only leading cause of death for which no diseasemodifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?

Original languageEnglish (US)
Article number111cm33
JournalScience translational medicine
Volume3
Issue number111
DOIs
StatePublished - Nov 30 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Testing the right target and right drug at the right stage'. Together they form a unique fingerprint.

  • Cite this